Advancing Eye Research: Cerulea Celebrates Two Years

The Melbourne Centre for Clinical Trials (MCCT) is pleased to celebrate two years of transformative research at Cerulea Clinical Trials who is a valued member of the MCCT network.

International Clinical Trials Day on the 20th of May commemorates what is widely recognised as the first clinical trial, conducted in 1747 by Scottish naval doctor James Lind. By comparing six treatments for scurvy among sailors, Lind demonstrated that citrus fruits led to rapid recovery, an early example of how systematic investigation can transform health outcomes. More than 250 years on, clinical trials remain central to advancing patient care and delivering new therapies.

As part of the MCCT ecosystem, Cerulea Clinical Trials is contributing to this legacy through research aimed at preventing blindness. Current trials span a range of conditions, from rare inherited retinal diseases such as retinitis pigmentosa to more common conditions including glaucoma. For patients who have historically had limited treatment options these trials are opening new possibilities for care and improved outcomes.

To mark this milestone, Cerulea is hosting its second anniversary event, offering a behind‑the‑scenes look at how ophthalmic clinical trials are designed and delivered, as well as insight into the participant experience in eye research.

These achievements reflect the collective effort of clinicians, research staff and participants across the MCCT network. Their collaboration has been central to Cerulea’s progress over the past two years and continues to support the advancement of high‑quality  patient‑centred clinical research.

This work has also been recognised more broadly, with Dr Catherine Jan awarded the Health Services Researcher Award at the Premier’s Prize for Medical Research. Following completion of her PhD at CERA, Dr Jan’s research focuses on improving glaucoma detection using artificial intelligence, with the potential to enable earlier diagnosis and more timely access to sight‑saving care.

Together, these developments highlight the important role of MCCT members, including Cerulea Clinical Trials, in driving innovation, strengthening collaboration and improving outcomes in clinical research.